Doximity filings document financial results, material events, governance actions, and capital-structure details for the operator of a digital platform for U.S. medical professionals. Recent Form 8-K disclosures cover quarterly results and related exhibits, finance and legal leadership changes, Regulation FD updates, and annual-meeting voting outcomes.
The company's regulatory record also includes shareholder voting matters tied to its Class A and Class B common stock structure, director elections, auditor ratification, material agreements, and other security-holder matters. These filings describe how Doximity reports operating performance, governance changes, voting mechanics, and formal public-company events.
Doximity, Inc. (DOCS) reported that Chief Financial Officer Matthew Sonefeldt had 15,311 shares of Class A Common Stock withheld on 2026-08-15 at $24.80 per share to satisfy tax withholding obligations arising from vesting of previously granted restricted stock units. This withholding followed an advance election by the company and is described as non-discretionary. After this event, Sonefeldt directly holds 486,238 shares of Class A Common Stock.
Doximity, Inc. reported that President Steven L. Zatz had 4,482 shares of Class A Common Stock withheld on 2026-08-15 at an implied value of $24.80 per share. The shares were retained by the company to satisfy tax withholding obligations upon vesting of previously granted RSUs, and are described as non-discretionary. Following this withholding, Zatz directly holds 51,864 shares of Class A Common Stock.
Doximity, Inc. Chief Executive Officer Jeffrey Tangney reported a withholding-related disposition of 8,505 shares of Class A Common Stock on 2026-08-15 at $24.80 per share. The shares were withheld by the company to satisfy tax withholding obligations upon vesting of previously granted restricted stock units and are described as non-discretionary, not an open-market trade. Following this event, Tangney directly holds 2,531,955 shares of Class A Common Stock.
An affiliate of DOCS filed a notice to sell restricted common stock. The planned transaction covers 1,770 shares of common stock to be sold through Morgan Stanley Smith Barney LLC Executive Financial Services, with an aggregate market value of $44,143.80 as of 08/13/2026 on the NYSE, in connection with a Stock Option Exercise. The filing also lists prior sales in the last three months: 1,732 shares for $38,138.64 on 07/15/2026 and 2,444 shares for $49,882.04 on 06/08/2026.
Doximity, Inc. director Timothy S. Cabral exercised and converted derivative holdings and sold common stock. On August 7, 2026, he exercised options for 7,500 Class B shares at an exercise price of $2.21 per share, converted them into 7,500 Class A shares, and sold those Class A shares at $39.11 per share under a Rule 10b5-1 trading plan. Following the option exercise, he held 326,000 stock options directly.
Doximity reported fiscal 2027 first‑quarter results with revenue of $156.6 million, up 7% year‑over‑year. Net income was $24.3 million with a 15.5% margin, down from $53.3 million and 36.5% a year earlier. Adjusted EBITDA was $74.8 million with a 47.7% margin.
GAAP gross margin was 84.9%, and non‑GAAP gross margin 87.5%. Operating cash flow was $42.0 million and free cash flow $39.6 million, both down more than 30% year‑over‑year. Cash and cash equivalents were $273.6 million and marketable securities $414.2 million as of June 30, 2026. The company repurchased $91.6 million of common stock in the quarter.
Management noted its Doximity Ask clinical AI assistant was the top‑performing U.S.-based model in the NOHARM benchmark and highlighted record engagement, with workflow active prescriber growth of more than 30% year‑over‑year and AI Search query growth of over 25% quarter‑over‑quarter. Doximity guides second‑quarter revenue to $170–$171 million and adjusted EBITDA to $80.5–$81.5 million, and full‑year revenue to $671–$681 million with adjusted EBITDA of $309–$329 million.
Doximity, Inc. granted Chief Executive Officer Jeffrey Tangney a stock option covering 2,480,000 shares of Class A Common Stock at an exercise price of $28.02 per share, expiring July 22, 2036.
The option vests in four equal annual installments beginning July 22, 2027, only if the share price equals or exceeds $28.02 for any 60 consecutive trading days between July 22, 2026 and July 22, 2030 and he remains in continuous service.
Doximity, Inc. President Steven L. Zatz received a grant of stock options for 150,000 shares of Class A Common Stock on July 22, 2026, with an exercise price of $20.49 per share. The options vest in three equal annual installments starting July 22, 2027, subject to his continuous service, and expire on July 22, 2036; all 150,000 options are held as direct beneficial ownership.